Since CEA is a clinically meaningful target due to its strong correlation with cancer progression, metastasis, and drug resistance, diverse clinical attempts are ongoing to develop various tool-based CEA-targeting anticancer drugs. This evidence concerns the gene CEACAM5 and cancer.